Cargando…
GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR)-activating mutation predicts excellent response to EGFR tyrosine kinase inhibitors (TKIs). However, lung cancer patients are often with unknown EGFR mutation status because there are little tumor specimen to determine. TKIs induce tum...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000015/ https://www.ncbi.nlm.nih.gov/pubmed/24758907 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.06 |
Ejemplares similares
-
BIM基因多态性与复治晚期非小细胞肺癌EGFR-TKI治疗疗效的关系
Publicado: (2013) -
吉西他滨联合长春瑞滨方案治疗复治中国晚期非小细胞肺癌患者的多中心回顾性研究
Publicado: (2012) -
吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析
Publicado: (2014) -
EGFR基因多态性对EGFR-TKIs治疗晚期NSCLC疗效和预后的影响
Publicado: (2013) -
BIM基因多态性对晚期肺腺癌一线EGFR-TKIs疗效影响回顾性研究
Publicado: (2017)